Navigation Links
Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
Date:6/24/2008

Presentations at Cardiostim World Congress Focus Attention on a New

Ablation Technology

CARLSBAD, Calif., June 24 /PRNewswire/ -- Ablation Frontiers, Inc. today announced that two studies reporting positive findings about its novel atrial fibrillation catheter ablation system were presented at this year's Cardiostim World Congress, a premier meeting for physicians that treat cardiac rhythm disorders.

Dr. Stefan Weber of the University Clinic at Regensburg, Germany, presented results of a study of 12 patients with paroxysmal atrial fibrillation (PAF). Using the company's PVAC(TM) (Pulmonary Vein Ablation Catheter) and GENius(TM) RF generator, Dr. Weber reported success in isolating 98 percent of pulmonary veins with a remarkably short average ablation time of 84 +/- 9 minutes. The total time of radiofrequency (RF) energy needed to successfully isolate the pulmonary veins was 22.4 +/- 2.9 minutes.

"We found that mapping and ablation of the pulmonary veins using a single catheter, without 3D navigation or robotic steering, could be performed safely and effectively with short procedure times," stated Dr. Weber. "Thus, this system may be of high interest for all centers who would like to increase throughput for AF ablation."

The second study, led by Dr. Christoph Scharf and presented by Dr. Lam Dang of Klinik Im Park Hospital in Zurich, Switzerland, utilized the same novel catheter ablation technology in a total of 45 patients with long standing persistent AF. This study utilized two additional catheters from Ablation Frontiers, MASC(TM) (Multi-Array Septal Catheter) and MAAC(TM) (Multi-Array Ablation Catheter) designed to find and ablate specific ablation targets called CFAEs (Complex Fractionated Atrial Electrograms). Six month follow up data was presented for 37 patients, with 78 percent free of AF after an average procedure time of 162 +/- 36 minutes. Dr Scharf noted the particularly low re-do procedure rate of 13.5% and the absence of left atrial flutters after the procedure.

"These early results are very promising and procedure times have been significantly reduced," stated Dr. Scharf. "Using unipolar:bipolar RF energy for the ablation is safer and more effective in our experience. This is an important aspect to this system, as tipped-catheters and conventional higher power RF generators have been associated with significant complications."

The company's innovative multi-electrode mapping and ablation catheters are used in conjunction with its duty-cycled radiofrequency (RF) generator. Each catheter's adaptable shape facilitates access to and good tissue contact with the left atrial regions that require ablation to terminate atrial fibrillation. The temperature controlled, power limited energy source was specifically designed to reduce the risk of complications seen with conventional higher-energy power sources.

"While isolation of the pulmonary veins can be effective in treating paroxysmal AF, long-standing persistent AF requires that other areas of the left atrium be specifically targeted. Conventional ablation technology offers only one therapeutic option for both disease states, which has produced moderate success, relatively high rates of complications, and long procedure times. Ablation Frontiers' family of catheters delivers innovative solutions for treating both paroxysmal and long standing persistent AF patients," stated Keegan Harper, Chief Executive Officer of Ablation Frontiers. "We are very gratified to see our products working in both AF patient populations with high success rates, very low complication rates, and considerably shortened procedure times."

Atrial fibrillation (AF) is a common and devastating cardiac rhythm disorder in which the heart's upper chambers beat in an extremely fast and chaotic rhythm. Symptoms may include palpitations, dizziness and shortness of breath. AF can present in different forms, including paroxysmal, in which the abnormal rhythm starts and stops on its own, or long-standing persistent, which does not stop on its own and cannot be stopped with currently available medical treatments (drugs or cardioversion). Left untreated, AF patients are at an increased risk for stroke and may also develop heart failure or other cardiac disorders.

About Ablation Frontiers

Ablation Frontiers is an emerging, venture-backed medical device company based in Carlsbad, California. Founded in 2004, Ablation Frontiers is dedicated to helping individuals suffering from atrial fibrillation and other cardiac arrhythmias. Working in concert with clinical experts in the field of ablation, the company is focused on developing and commercializing innovative products designed to make ablation procedures safer and less time consuming, thereby making it possible for more individuals to benefit from this life-enhancing therapy. In late 2006, Ablation Frontiers received the CE Mark to begin marketing in the European Union with its portfolio of anatomical-based catheters and a multi-channel RF generator. To learn more about the company, visit http://www.ablationfrontiers.com.


'/>"/>
SOURCE Ablation Frontiers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
2. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
5. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
6. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
7. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
8. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
9. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):